Get started
Author

Édina Poletto

Observed names: E Poletto, E. Poletto, Edina Poletto, Poletto Edina, Poletto, Edina, Poletto, Édina
ORCID: 0000-0003-0554-0295
Observed ORCID: 0000-0003-0554-0295
OpenAlex ID: A5067093922
In vivo genome editing of mucopolysaccharidosis I mice using the CRISPR/Cas9 system
2018 · Roselena Silvestri Schuh, Édina Poletto, et al. · Journal of Controlled Release · 69
Engineering monocyte/macrophage−specific glucocerebrosidase expression in human hematopoietic stem cells using genome editing
2020 · Samantha G. Scharenberg, Edina Poletto, et al. · Nature Communications · 57
PDF
Worldwide distribution of common IDUA pathogenic variants
2018 · E. Poletto, G. Pasqualim, et al. · Clinical Genetics · 45
Genome Editing for Mucopolysaccharidoses
2020 · Edina Poletto, Guilherme Baldo, et al. · International Journal of Molecular Sciences · 43
PDF
Neonatal nonviral gene editing with the CRISPR/Cas9 system improves some cardiovascular, respiratory, and bone disease features of the mucopolysaccharidosis I phenotype in mice
2019 · Roselena Silvestri Schuh, Esteban Alberto Gonzalez, et al. · Gene Therapy · 37
Cathepsin B inhibition attenuates cardiovascular pathology in mucopolysaccharidosis I mice
2018 · Esteban Alberto Gonzalez, Giselle Renata Martins, et al. · Life Sciences · 31
Nasal Administration of Cationic Nanoemulsions as Nucleic Acids Delivery Systems Aiming at Mucopolysaccharidosis Type I Gene Therapy
2018 · Roselena Silvestri Schuh, Juliana Bidone, et al. · Pharmaceutical Research · 29
Physicochemical properties of cationic nanoemulsions and liposomes obtained by microfluidization complexed with a single plasmid or along with an oligonucleotide: Implications for CRISPR/Cas technology
2018 · Roselena S. Schuh, Édina Poletto, et al. · Journal of Colloid and Interface Science · 26
Progressive heart disease in mucopolysaccharidosis type I mice may be mediated by increased cathepsin B activity
2017 · Guilherme Baldo, Angela Maria Vicente Tavares, et al. · Cardiovascular Pathology · 23
Quantification of lysosphingomyelin and lysosphingomyelin-509 for the screening of acid sphingomyelinase deficiency
2022 · Francyne Kubaski, Alberto Burlina, et al. · Orphanet Journal of Rare Diseases · 21
PDF
Brain and visceral gene editing of mucopolysaccharidosis I mice by nasal delivery of the CRISPR/Cas9 system
2022 · Luisa Natalia Pimentel Vera, Roselena Silvestri Schuh, et al. · The Journal of Gene Medicine · 19
Pilot study of newborn screening for six lysosomal diseases in Brazil
2023 · Francyne Kubaski, Ines Sousa, et al. · Molecular Genetics and Metabolism · 17
Improved engraftment and therapeutic efficacy by human genome-edited hematopoietic stem cells with Busulfan-based myeloablation
2022 · Edina Poletto, Pasqualina Colella, et al. · Molecular Therapy — Methods & Clinical Development · 16
PDF
Diagnosis and Emerging Treatment Strategies for Mucopolysaccharidosis VII (Sly Syndrome)
2022 · Fabiano de Oliveira Poswar, Johanna Henriques Nehm, et al. · Therapeutics and Clinical Risk Management · 15
PDF
Evidence for inflammasome activation in the brain of mucopolysaccharidosis type II mice
2020 · A. S. Azambuja, L. N. Pimentel-Vera, et al. · Metabolic Brain Disease · 14
Intra-articular nonviral gene therapy in mucopolysaccharidosis I mice
2018 · Juliana Bidone, Roselena Silvestri Schuh, et al. · International Journal of Pharmaceutics · 14
Evaluation of oxidative stress and mitochondrial function in a type II mucopolysaccharidosis cellular model: in vitro effects of genistein and coenzyme Q10
2022 · Carlos Eduardo Diaz Jacques, Franciele Fátima Lopes, et al. · Metabolic Brain Disease · 13
Gene editing strategies to treat lysosomal disorders: The example of mucopolysaccharidoses
2022 · Flávia Nathiely Silveira Fachel, Lariane Frâncio, et al. · Advanced Drug Delivery Reviews · 9
Laronidase-loaded liposomes reach the brain and other hard-to-treat organs after noninvasive nasal administration
2024 · Roselena Silvestri Schuh, Eduarda Piovesan Franceschi, et al. · International Journal of Pharmaceutics · 8
Production of antimicrobial metabolites against pathogenic bacteria and yeasts by Fusarium oxysporum in submerged culture processes
2021 · Liliane Poleto, Letícia Osório da Rosa, et al. · Bioprocess and Biosystems Engineering · 8
Basic and translational research in rare diseases in low- and middle-income countries: challenges and solutions
2024 · Graziella Rodrigues, Edina Poletto, et al. · Journal of Community Genetics · 7
PDF
Effects of gene therapy on cardiovascular symptoms of lysosomal storage diseases
2019 · Edina Poletto, Gabriela Pasqualim, et al. · Genetics and Molecular Biology · 7
PDF
Losartan improves aortic dilatation and cardiovascular disease in mucopolysaccharidosis I
2017 · Esteban Alberto Gonzalez, Angela Maria Vicente Tavares, et al. · Journal of Inherited Metabolic Disease · 7
Experience of the NPC Brazil Network with a Comprehensive Program for the Screening and Diagnosis of Niemann-Pick Disease Type C
2022 · Francyne Kubaski, Alberto Burlina, et al. · International Journal of Neonatal Screening · 6
PDF
Biochemical diagnosis of aromatic-L-amino acid decarboxylase deficiency (AADCD) by assay of AADC activity in plasma using liquid chromatography/tandem mass spectrometry
2022 · Gabriel Civallero, Francyne Kubaski, et al. · Molecular Genetics and Metabolism Reports · 6
Works count: 86
Citation count: 589
H-index: 14
I10-index: 17
Year
Topic
Type